Circulating and intratumoral NK-cell subsets in patients with cHL and DLBCL and in the blood of healthy participants. (A) Pretherapy circulating CD3⁻CD56⁺ NK cells in patients with cHL and DLBCL and healthy participants. (B) Representative fluorescence-activated cell sorter plots of CD3⁻CD56^dimCD16⁺ and CD3⁻CD56^hiCD16^-ve subsets of circulating NK cells in healthy participants and patients with cHL and DLBCL. Percentage of CD3⁻CD56^hiCD16^-ve as a proportion of CD3⁻CD56⁺ NK cells is shown. (C) Ratios of CD3⁻CD56^dimCD16⁺ and CD3⁻CD56^hiCD16^-ve subsets in circulating and intratumoral NK cells in patients with cHL and DLBCL, and from the circulation and nodes in healthy participants. Asterisks denote significance: *P < .05; **P < .01; ***P < .001; ****P < .0001. NS, not significant.